logo

Arqule Inc. (ARQL)



Trade ARQL now with
  Date
  Headline
5/7/2018 7:01:58 AM ArQule Q1 Net Loss $6.53 Mln Or $0.07/Shr Vs Loss Of $7.58 Mln Or $0.11/Shr Last Eyar
4/17/2018 7:01:24 AM ArQule And Basilea Enter License Deal For Derazantinib In The US, EU, Japan And Rest Of World Excluding Greater China
4/17/2018 1:18:10 AM Basilea Pharmaceutica Enters Into License Deal With ArQule For Oncology Drug Candidate ARQ 087
3/5/2018 7:00:49 AM ArQule Q4 Loss Per Share $0.09 Vs Loss $0.10 Last Year
2/7/2018 7:03:13 AM Roivant Sciences And ArQule Enter License Agreement For Derazantinib In China
2/2/2018 7:29:38 PM B. Riley FBR Starts ArQule Inc. (ARQL) At Buy With $3 Price Target
11/21/2017 7:01:13 AM ArQule Announces Dosing In A Registrational Trial Of FGFR Inhibitor, Derazantinib, For Intrahepatic Cholangiocarcinoma